South Korea’s government drug agency cleared the way Thursday for commercial sales of what it called the world’s first approved medicine using stem cells collected from other people.
Cartistem, developed by Seoul-based Medipost, will help regenerate knee cartilage using stem cells developed from newborns’ umbilical cord blood, the Korea Food and Drug Administration said.
“Cartistem is… the world’s first approved allogeneic (taken from different individuals of the same species) stem cell drug, that can offer new opportunity for treatment of patients with degenerative arthritis,” the administration said in a statement.
Medipost said 27 billion won ($23.8 million) from private investors and government
A stem cell researcher at Seoul National University (SNU) is suspected of fabricating 14 studies submitted to international scientific journals for publication, the school said Monday.
The misconduct of the researcher, if proven to be true, could deal a severe blow to the nation’s efforts to revive its reputation as a world leader in stem cell research following data manipulation in 2005 by then SNU professor Hwang Woo-suk.
“We’re following the matter closely,” a public relations official at the school said. “We are conducting an internal investigation while waiting for the opinion of the international journals.” The researcher is veterinary professor
Stem Cell Research Brings About Another Miracle
Korean doctors have apparently regrown a patient’s jawbone using the patient’s own Adult Stem Cells in yet another amazing miracle that Adult Stem Cell research has brought us.
An 18 year old Korean boy who had to have most of his jawbone and his teeth removed due to a tumor […]